Abstract
Expression of Gp100 is most useful clinically as a diagnostic marker of melanoma. Its role as a therapeutic target is currently under investigation. The peptide gp100:209-217 (210 M) in Montanide ISA-51 (incomplete Freund's adjuvant) in combination with interleukin-2 (IL-2) demonstrated clinical activity which was significantly higher than IL-2 alone but most importantly established proof of biologic activity and relevance for future study (Schwartzentruber et al. 2011).
Author supplied keywords
Cite
CITATION STYLE
APA
Schwartzentruber, D. (2017). gp100. In Cancer Therapeutic Targets (Vol. 1–2, pp. 261–266). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_26
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free